Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06700824

A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients with Acute Ischemic Stroke (MATRISS-II)

MATRISS-II. Matrix Therapy to Reduce Ischemic Stroke Sequelae-II. a Randomized-double Blinded- Placebo Controlled Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients with Acute Ischemic Stroke

Sponsor: Euraxi Pharma

Conditions Endovascular Thrombectomy Ischemic Cerebrovascular Accident

Interventions OTR4132 Placebo

Updated 2 times since 2024 Last updated: Nov 22, 2024 Started: Feb 28, 2025 Primary completion: Mar 31, 2026 Completion: Mar 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Endovascular Thrombectomy and Ischemic Cerebrovascular Accident and is currently actively recruiting participants. Euraxi Pharma leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Not Yet Recruiting PHASE2
Dec 2024 — Sep 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Euraxi Pharma
Organ, Tissue, Regeneration, Repair and Replacement

Data source: Organ, Tissue, Regeneration, Repair and Replacement

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bordeaux, France , Brest, France , Créteil, France , Fort de France, France , Grenoble, France , Lille, France , Marseille, France , Nancy, France , Nantes, France , Paris, France and 3 more locations